Loading…
Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.
Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.
Sells steroid active ingredients in bulk to makers of finished tablets and injections, mostly generic drugmakers, priced by grade, with volumes and prices following hormone-drug demand and Chinese raw-material costs. Finished formulations are a smaller extension of the same chemistry.
In one line: A Chinese steroid-API supplier.
Moat: narrow (scale, regulatory licence). Large-scale steroid API production with multiple regulatory filings is costly for smaller rivals to match.
Headquarters: Xianju, Zhejiang, China · Employees: 3,209
Size Zhejiang Xianju Pharmaceutical (002332.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 1813th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.98 on 6 Nov 2026.
Performance Over six months the shares gained 2.4%, against -12.3% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 7.6% over the last twelve months (peer median +17.6%); the operating margin is 11.3% (peer median 1.8%).
Valuation It trades at 18.6× forward earnings against a peer median of 16.1× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.4% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.86B | CN¥3.73B | CN¥3.98B | CN¥4.09B | CN¥4.34B |
| Revenue growth | — | -6% | -3% | -6% | — |
| Gross profit | CN¥2.46B | CN¥2.21B | CN¥2.23B | CN¥2.10B | CN¥2.46B |
| EBITDA | n/a | CN¥640M | CN¥839M | CN¥816M | CN¥864M |
| Net income | CN¥465M | CN¥450M | CN¥397M | CN¥563M | CN¥749M |
| Free cash flow | CN¥578M | CN¥40.6M | CN¥195M | CN¥364M | CN¥327M |
| Capital expenditure | CN¥160M | CN¥209M | CN¥208M | CN¥235M | CN¥283M |
| Total debt | CN¥218M | CN¥378M | CN¥81.3M | CN¥446M | CN¥426M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical 002332.SZ | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | $801M | -14% | -12% | 3% | n/a | 3.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002332.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -7.5% | 4th highest of 21 |
| 6-month return | +2.4% | -12.3% | 5th highest of 21 |
| Distance from 52-week high | -10.7% | -38.7% | highest of 21 |
| Revenue growth (TTM) | +7.6% | +17.6% | 6th lowest of 17 |
| Operating margin | 11.3% | 1.8% | 6th highest of 17 |
| Forward P/E | 18.6× | 16.1× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 0.8% | 4th least demanding of 7 |
| Growth delivered (Del g) | -1.3% | +13.3% | 2nd lowest of 7 |
| Hurdle (Req g minus delivered) | +1.6 pp | -17.8 pp | 3rd most demanding of 7 |
| ROIC minus cost of capital | +2.7 pp | -5.2 pp | 4th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |